RhumbLine Advisers
NVCT icon

RhumbLine Advisers’s Nuvectis Pharma NVCT Stock Holding History

RhumbLine Advisers’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$66.9K Buy
8,657
+224
+3% +$1.92K ﹤0.01% 3534
2025
Q4 		$63.7K Sell
8,433
-2,897
-26% -$18.9K ﹤0.01% 3591
2025
Q3 		$68.2K Sell
11,330
-1,348
-11% -$9.27K ﹤0.01% 3603
2025
Q2 		$94.7K Buy
+12,678
New +$115K ﹤0.01% 3547
2024
Q3 		– Sell
-1,871
Closed -$11.8K – 4288
2024
Q2 		$11.8K Sell
1,871
-5,631
-75% -$38.3K ﹤0.01% 3959
2024
Q1 		$61.5K Buy
7,502
+229
+3% +$1.95K ﹤0.01% 3578
2023
Q4 		$60.7K Hold
7,273
– – ﹤0.01% 3581
2023
Q3 		$93.7K Buy
7,273
+495
+7% +$7.17K ﹤0.01% 3485
2023
Q2 		$108K Buy
+6,778
New +$108K ﹤0.01% 3498

Other funds holding NVCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

RhumbLine Advisers's NVCT Position: Q1 2026 in Review

RhumbLine Advisers increased its Nuvectis Pharma (NVCT) stake by 2.7% in Q1 2026, buying an estimated $1.92K and bringing the position to 8,657 shares worth $66.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3534.

RhumbLine Advisers first reported a position in NVCT in Q2 2023 and has held it in 9 quarters since. The position peaked at $108K in Q2 2023. 62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

  • RhumbLine Advisers held 8,657 shares of Nuvectis Pharma worth $66.9K as of Q1 2026.
  • RhumbLine Advisers bought 224 Nuvectis Pharma shares in Q1 2026, an estimated $1.92K.
  • Nuvectis Pharma made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3534 holding.
  • RhumbLine Advisers first reported a position in Nuvectis Pharma in Q2 2023 and has held it in 9 quarters since.
  • RhumbLine Advisers's Nuvectis Pharma position peaked at $108K in Q2 2023.
  • 62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.